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1. Introduction 
The administration of inhibitors of DNA synthesis 
as antiviral gents is limited by their toxicity to pro- 
liferating cells. Therefore the treatment of diseases 
caused by deoxyriboviruses growing in on-dividing 
cells would be improved by selectively concentrating 
these drugs in the infected cells [l-4]. Concentration 
of trifluorothymidine [2], adenine-9Q-D-arabinofur- 
anoside (ara-A) and ara-A monophosphate (ara-AMP) 
[3] inside hepatocytes has been achieved in mice with 
Ecfromelia virus-hepatitis by injecting these drugs 
coupled to asialofetuin (AF). Fetuin, a glycoprotein 
from fetal calf serum, when administered to mammals 
in a desialylated form, binds to a receptor for galac- 
tosyl-terminating glycoproteins present only on 
hepatocytes and consequently is selectively internal- 
ized in these cells where it is digested in lysosomes 
[S-7]. It has been suggested [8,9] that a protein may 
be made to penetrate into a cell which it does not 
normally enter by itself, by coupling it with a smaller 
molecule for which a specific binding site exists on 
the cell membrane. In agreement with this hypothesis 
it was observed that proteins, after coupling to the 
asialoglycopeptide of fetuin [lo] or simply to lactose 
[ 11 ,121, enter into parenchymal liver cells. 
We have found that lactosaminated serum albumin 
(L-SA) can substitute AF as a hepatotropic arrier 
of ara-AMP. GSA has the advantage over AF of being 
easily obtained in the amounts required for clinical 
purposes. Moreover the use of homologous GSA 
might reduce the risk of an immune response against 
the conjugate. ara-AMP displays the same antiviral 
activity as ara-A [ 131; both drugs must be converted 
to ara-A triphosphate in order to inhibit DNA synthe- 
sis [ 14,151. ara-AMP was chosen because it can be 
easily bound to proteins by means of water-soluble 
carbodiimides [3]. 
2. Materials and methods 
2.1. L-SA -ara-AMP conjugates 
Lactose was coupled to e-NH2 of lysine residues of 
rabbit (RSA) or human (I-ISA) serum albumin by 
reductive amination with cyanoborhydride [ 16,171. 
The albumin concentration was determined as in 
[ 181. The amount of sugar conjugated to protein was 
established by the phenol/sulfuric acid method [ 191 
calibrated against galactose. In different preparations 
of LSA increasing amounts of lactose were coupled 
as a function of time of reaction [ 11 ,171. ara-AMP 
was conjugated to LSA by the use of 1 ethyl3- 
(dimethyl-aminopropyl)-carbodiimide, following the 
procedure used to bind this drug to AF [3]. Conjuga 
tion takes place probably by formation of an amide 
bond between the e-NH2 group of lysine in the pro- 
tein and the phosphate group of ara-AMP [20]. After 
gel chromatography on Sephadex G-100 [3 ] the frac- 
tions corresponding to the monomeric form of the 
conjugate were pooled, dialyzed against water and 
lyophilized. One LRSA-ara-AMP and 3 LHSA-ara- 
AMP conjugates were prepared. The molar ratio ara- 
AMP/albumin was determined spectrophotometri- 
tally. During ara-AMP conjugation the amount of 
galactosyl residues attached to albumin was found to 
decrease. The molar ratio sugar/albumin was there- 
fore measured again in GSA-ara-AMP conjugates 
taking into consideration the contribution given by 
arabinose in the phenol/sulphur reaction. 
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2.2. [methyl-3H/Thymidine incorporation into DNA Table 1 
in liver, intestine and bone marrow of Ectromelia 
virus-infected mice 
In each experiment purified [21,22] Ectromelia 
Effect of L-SA-ara-AMP conjugates on plasma clearance of 
“C-labelled AF 
virus (Hampstead mouse strain) was injected intrave- 
nously (i.v.) into 14 Swiss female mice (26-28 g) at 
the multiplicity of 2 X lo5 p.f.u./g body wt. After 
44.5 h mice were divided in 2 groups of 7 animals 
each. Animals of one group were used as controls. 
Animals of the other group were inoculated intra- 
peritoneally (i.p.) with 9erithro-(2-hydroxyl-3-nonyl)- 
adenine (EHNA) (an inhibitor of ara-A deamination 
[23])(3 pg/g body wt) and 15 min later received an 
i.v. injection of the antiviral compound to be tested. 
After 45 min animals of treated and control groups 
were injected i.p. with [methy2-3H]thymidine (25 Ci/ 
mmol) at 30 &i/animal. After 30 min mice were 
killed and liver, a tract of intestine (4 cm long starting 
from pylorus) and bone marrow from femurs were 
rapidly removed. DNA was extracted according to 
[24], the radioactivity was counted and the concen- 
tration measured as in [25]. Administration of EHNA 
was necessary [3] because ara-A is >lOO-times less 
active in rodents than in primates, due to its more 
rapid metabolism [26]. EHNA administered alone to 
Ectromelia virus-infected mice, did not affect thymi- 
dine incorporation in liver, intestine or bone marrow. 
Exp. 
no. 
Compounds injected 
with “C-labelled AF 
1 None 1175 f 420 
2 AF 2320 + 156 
3 L ,,.,-RSA-ara-AMP,, 2431 f 248 
4 L ,,.,-HSA-ara-AMP,,, 1197 f 313 
5 L ,,.,-HSA-ara-AMP,., 2201 + 293 
6 L ,,.,-HSA-ara-AMP,,., 1953+ 2 
7 L ,,.,-HSA-ara-AMP,,., 2224 f 20 
Swiss female mice (26-28 g) were injected i.v. with 2 pg/g 
body wt of “‘C-1abelled AF (7 X lo5 dpm/mg) prepared 
according to [36]. Cold AF or conjugates were administered 
simultaneously with [14C]AF at 20 pg/g body wt except in 
expt 5 in which the conjugate was injected at 33 pg/g (an 
amount equimolecular to 20 pg AF). After 5 min animals 
were killed and the radioactivity of plasma was measured. 
Each entry represents the mean value of results from 2 ani- 
mals. Number subscript to L and ara-AMP represents the 
molar ratios of sugar/albumin and ara-AMP/albumin. respect- 
ively 
3. Results and discussion 
Table 2 
Hybridization to Ectromeh virus DNA of liver [3H]DNA 
from normal and Ectromelia virus-infected mice 
L-SA-ara-AMP conjugates interact with the hepatic 
receptor for asialoglycoproteins; in fact, as shown in 
table 1, they competitively inhibited the blood clear- 
ance of [ 14C] AF in mice. 
Free ara-A and ara-AMP as well as coupled ara- 
AMP were administered to mice 44.75 h after infec- 
tion with Ectromelia virus and their effect on thymi- 
dine incorporation into DNA in liver, intestine and 
bone marrow was determined. After 46 h Ectromelia 
virus infection the newly synthesized liver DNA 
hybridizes with viral DNA (table 2); electron micro- 
scopic observations (M. Derenzini, unpublished) 
demonstrated that at this time the infection is wide- 
spread to the hepatic parenchyma in agreement with 
[27] and that the number and size of viral factories as 
well as the number of viral particles they contain are 
several times higher in parenchymal than in sinusoidal 
cells. This indicates that in liver, in our experimental 
conditions, most of the virus DNA synthesis occurred 
DNA immobilized Liver [‘H]DNA added cpm retained 
on filters to filters from on filters 
Ecbomelia virus Normal mice 31 
Ecbomeh virus Eetromelia virus 
-infected mice 522 
Salmon sperm Normal mice 29 
Salmon sperm Ectromelia virus 
-infected mice 20 
[methyZ-3H]Thymidine (47.5 Ci/mmol) was injected i.p. 
(100 @X/animal) to normal and Ectromefia virus-infected 
mice (46 h post infection). After 30 min mice were killed 
and the liver was removed. DNA was extracted from purified 
Ectromelia virus and from liver as in [37]. Filter hybridiza- 
tion was performed as in [38]. Ecfromelia virus or salmon 
sperm DNA (5 pg) were immobilized on each filter and 
8 X 10’ cpm of labelled liver DNA were added. Each result 
represents the mean value from 2 filters 
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Table 3 
Inhibition of thymidine incorporation i to DNA in liver, intestine and bone marrow of Ectromelia 
virus-infected mice after injection of free ara-A, ara-AMP and conjugated ara-AMP 
Exp. 
no. 
Compound Injected ara-A administered Inhibition of thymidine incorporation 
(nmol/g body wt) 
Liver Intestine Bone marrow 
1 ara-A 
2 ara-A 
3 ara-AMP 
4 L ,,.,-RSA-ara-AMP,., 
5 L ,,.,-RSAara-AMP,., 
6 L ,,.,-HSA-ara-AMP,., 
7 L ,,.,-HSA-ara-AMP,., 
8 L ,,.,-HSA-ara-AMP,,., 
9 L ,,.,-HSA-ara-AMP,,., 
10 L ,,.,-HSA-ara-AMP,,., 
9.4 
13.0 
34.5 
1.0(20.7)a 
2.0(41.5) 
1.6(16.6) 
4.2(43.5) 
4.9(35) 
4.0(28.2) 
4.8(35) 
45(S)C 
50(S) 
50(S) 
30(S) 
53(S) 
21(NS)C 
43(S) 
50(S) 
48(S) 
58(S) 
44(S) 
55(S) 
61(S) 
0 
23(S) 
0 
0 
19(NS) 
0 
18(NS) 
0 
25(s) 
43(S) 
n.d.b 
n.d. b 
0 
0 
2(NS) 
0 
0 
a In parenthesis the amount of conjugate injected (in rg/g body wt); b n.d., not done 
c Results were statistically evaluated by means of Student’s t-test. The difference was considered 
statistically significant (S) or not significant (NS) for P < or > 0.05, respectively 
in hepatocytes. As shown in table 3, and in agreement 
with [3], free ara-A and ara-AMP inhibited DNA syn- 
thesis to the same extent in liver and intestine; they 
produced a smaller inhibition in bone marrow. On the 
contrary inhibition of DNA synthesis caused by ara- 
AMP coupled to L-SA was higher in liver than in 
intestine where in some experiments thymidine 
incorporation was completely unaffected. Conjugated 
ara-AMP did not interfere with DNA synthesis in 
bone marrow. Doses of conjugated ara-AMP lower 
than those of free drugs were required to cause a 
comparable inhibition of DNA synthesis in liver. 
These results indicate that, after injection of the 
conjugates, ara-AMP is concentrated in a pharma- 
cologically active form into hepatocytes. Since the 
ester bond linking phosphate to ara-A might be 
broken down in hepatocyte lysosomes, it can not be 
excluded that the drug released free from the conju- 
gates was ara-A and not ara-AMP. 
Viral hepatitis B occurs endemically in all parts of 
the world and is a major medical problem because of 
the impact that it has on blood transfusion services 
and its association with chronic liver disease and with 
primary liver cancer [28]. In chronic hepatitis B, 
ara-A, administered alone or in combination with 
interferon, inhibits viral replication [29-321 and in 
some patients brings about a disappearance of Dane 
particles from blood [29,30] and liver [30]. However, 
ara-A produces side effects, such as gastrointestinal 
and neurological disturbances, which can necessitate 
discontinuation of the therapy [33]; it also cause a 
marked lymphocytopenia which may affect the out- 
come of the treatment since succesful antiviral therapy 
appears to require the cooperation of the host immune 
response [34]. Selective concentration of ara-A or 
ara-AMP into hepatocytes, as achieved by coupling 
ara-AMP to GSA, should reduce the side effects and 
improve the efficacy of the treatment. 
The possibility exists that antibodies are produced 
against ara-AMP conjugates, even if they are prepared 
with homologous GSA and in further experiments we 
will study this problem in laboratory animals. How- 
ever, L-SA conjugates, even if complexed with anti- 
bodies, should maintain their original target and 
penetrate selectively into hepatocytes. Indeed the 
capacity of the hepatic receptor for galactosyl ter- 
minating lycoproteins to bind and internalize immune 
complexes has been shown [35]: the clearance of 
IgG-albumin complexes was mediated by the binding 
of galactosyl residues on IgG to the specific receptor 
on hepatocytes followed by uptake of the immune 
complexes by parenchymal liver cells. 
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